Literature DB >> 12709831

Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.

Karoline Spaepen1, Sigrid Stroobants, Gregor Verhoef, Luc Mortelmans.   

Abstract

Lymphomas are a heterogeneous group of diseases with differing histopathology, clinical behaviour, response to therapy and outcome. Lymphomas are highly sensitive to chemotherapy and radiotherapy, and the recent developments in treatment have considerably improved clinical outcome. However, there is increasing recognition that this has been at the cost of long-term treatment-related effects in a relatively young patient population. Thus, one of the most challenging aspects in the imaging of lymphoma patients is tailoring the intensity of the treatment to the individual patient. This paper reviews recently published data concerning the use of fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for therapy monitoring in lymphoma patients and highlights the shortcomings and future directions. A temporary strategy for the implementation of [(18)F]FDG-PET in the management of lymphoma patients is proposed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12709831     DOI： 10.1007/s00259-003-1166-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  33 in total

1.  Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.

Authors:  T Torizuka; K R Zasadny; P V Kison; S G Rommelfanger; M S Kaminski; R L Wahl
Journal:  J Nucl Med       Date:  2000-06       Impact factor: 10.057

2.  Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Authors:  K Spaepen; S Stroobants; P Dupont; J Thomas; P Vandenberghe; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

3.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

4.  Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.

Authors:  U Cremerius; U Fabry; J E Wildberger; M Zimny; P Reinartz; B Nowak; W Schaefer; U Buell; R Osieka
Journal:  Bone Marrow Transplant       Date:  2002-07       Impact factor: 5.483

5.  Thoracic CT-scanning follow-up of residual mediastinal masses after treatment of Hodgkin's disease.

Authors:  F Thomas; J M Cosset; P Cherel; N Renaudy; P Carde; J D Piekarski
Journal:  Radiother Oncol       Date:  1988-02       Impact factor: 6.280

6.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

7.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

8.  Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.

Authors:  M Hill; D Cunningham; D MacVicar; A Roldan; J Husband; R McCready; J Mansi; S Milan; T Hickish
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

9.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

10.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

Authors:  K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976
View more
  19 in total

1.  FDG-PET in infectious and inflammatory disease.

Authors:  Wim J G Oyen; Luigi Mansi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-02       Impact factor: 9.236

Review 2.  Positron emission tomography in the management of lymphomas: a summary.

Authors:  M J O'Doherty; P J Hoskin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

3.  Influence of selected b values on ADC quantification in diffusion-weighted MRI. Comment on Punwani et al.: Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI?

Authors:  Adriano M Priola; Sandro M Priola
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-29       Impact factor: 9.236

4.  An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

Authors:  Emmanuel Itti; Michel Meignan; Alina Berriolo-Riedinger; Alberto Biggi; Amanda F Cashen; Pierre Véra; Hervé Tilly; Barry A Siegel; Andrea Gallamini; René-Olivier Casasnovas; Corinne Haioun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-07       Impact factor: 9.236

5.  (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.

Authors:  T Gmeiner Stopar; I Mlinaric-Rascan; J Fettich; S Hojker; S J Mather
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-20       Impact factor: 9.236

6.  Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  Christian la Fougère; Walter Hundt; Nicole Bröckel; Thomas Pfluger; Alexander Haug; Bernhard Scher; Marcus Hacker; Klaus Hahn; Maximilan Reiser; Reinhold Tiling
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-21       Impact factor: 9.236

7.  Evolution of lymphoma staging and response evaluation: current limitations and future directions.

Authors:  Joel Cunningham; Sunil Iyengar; Bhupinder Sharma
Journal:  Nat Rev Clin Oncol       Date:  2017-06-13       Impact factor: 66.675

Review 8.  Imaging in clinical trials.

Authors:  P Murphy; D-M Koh
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

9.  Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.

Authors:  Thomas Cazaentre; Franck Morschhauser; Maximilien Vermandel; Nacim Betrouni; Thierry Prangère; Marc Steinling; Damien Huglo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-30       Impact factor: 9.236

10.  Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.

Authors:  J Dose-Schwarz; R Tiling; S Avril-Sassen; S Mahner; A Lebeau; C Weber; M Schwaiger; F Jänicke; M Untch; N Avril
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.